Intestinal mononuclear phagocytes as prognostic biomarker for crohn's disease
US-2024425923-A1 · Dec 26, 2024 · US
Composition for diagnosing or treating kidney disease
US12590332B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12590332-B2 |
| Application number | US-202118010459-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 15, 2021 |
| Priority date | Jun 15, 2020 |
| Publication date | Mar 31, 2026 |
| Grant date | Mar 31, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a composition for diagnosing or treating kidney disease, and specifically, provides a composition for diagnosing kidney disease, including VSIG4 or a gene coding same as an active ingredient, and a pharmaceutical composition for preventing or treating kidney disease, including an expression or activity inhibitor for VSIG4 or a gene coding same as an active ingredient.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A method of screening a therapeutic agent for treating a kidney disease, comprising: isolating a biological sample from a patient suspected of having the kidney disease; treating the biological sample with a test substance; measuring an expression level of VSIG4 mRNA in the biological sample treated with the test substance by reverse transcription polymerase chain reaction (RT-PCR) using a forward primer having the nucleotide sequence set forth in SEQ ID NO: 1 and a reverse primer having the nucleotide sequence set forth in SEQ ID NO: 2; measuring an expression level of the VSIG4 protein in the biological sample treated with the test substance by enzyme-linked immunosorbent assay (ELISA) using an anti-VSIG4 antibody; and selecting the test substance as a therapeutic agent for treating the kidney disease when the expression level of VSIG4 or a gene encoding VSIG4 is reduced in the biological sample treated with the test substance as compared to a control sample not treated with the test substance, wherein the kidney disease is selected from the group consisting of diabetic nephropathy, hypertensive nephropathy, glomerulonephritis, polycystic kidney disease, and urinary trace obstruction.
Assignees
Inventors
Classifications
Expression markers · CPC title
Screening for pharmacological compounds · CPC title
Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title
Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12590332B2 cover?
- The present invention relates to a composition for diagnosing or treating kidney disease, and specifically, provides a composition for diagnosing kidney disease, including VSIG4 or a gene coding same as an active ingredient, and a pharmaceutical composition for preventing or treating kidney disease, including an expression or activity inhibitor for VSIG4 or a gene coding same as an active ingre…
- Who is the assignee on this patent?
- Univ Inje Ind Acad Coop Found
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/6883. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).